Boca Pharmacal receives FDA approval for Methimazole tablets
Boca Pharmacal CEO Robert Edwards said this is the company’s first approval this year and it is expecting a second before the end of the first quarter. "As
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
According to the study, patients with more severe symptoms achieved a greater improvement following treatment with the ToleroMune T-cell vaccine than those on placebo (p=0.05). Therandomized, double-blind studywas
The Revitas revenue management solution allows pharmaceutical manufacturers to minimise the payment of erroneous claims for rebate and administrative fee payments by validating rebate claims for individual prescriptions.